Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company's lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The compa… Read more
Dextech Medical AB (LQ0) - Total Assets
Latest total assets as of September 2025: €24.25 Million EUR
Based on the latest financial reports, Dextech Medical AB (LQ0) holds total assets worth €24.25 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dextech Medical AB - Total Assets Trend (2022–2025)
This chart illustrates how Dextech Medical AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dextech Medical AB - Asset Composition Analysis
Current Asset Composition (June 2025)
Dextech Medical AB's total assets of €24.25 Million consist of 60.5% current assets and 39.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 58.6% |
| Accounts Receivable | €473.00K | 1.9% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €9.92 Million | 39.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Dextech Medical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dextech Medical AB's current assets represent 60.5% of total assets in 2025, a decrease from 91.0% in 2022.
- Cash Position: Cash and equivalents constituted 58.6% of total assets in 2025, down from 89.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 9.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 39.5% of total assets.
Dextech Medical AB Competitors by Total Assets
Key competitors of Dextech Medical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Dextech Medical AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dextech Medical AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Dextech Medical AB is currently not profitable relative to its asset base.
Dextech Medical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 43.24 | 27.05 | 27.05 |
| Quick Ratio | 43.24 | 27.05 | 27.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €14.23 Million | € 17.90 Million | € 17.90 Million |
Dextech Medical AB - Advanced Valuation Insights
This section examines the relationship between Dextech Medical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -17.9% |
| Total Assets | €25.10 Million |
| Market Capitalization | $7.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dextech Medical AB's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Dextech Medical AB's assets decreased by 17.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Dextech Medical AB (2022–2025)
The table below shows the annual total assets of Dextech Medical AB from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €25.10 Million | -17.94% |
| 2024-06-30 | €30.59 Million | -12.68% |
| 2023-06-30 | €35.03 Million | -11.51% |
| 2022-06-30 | €39.59 Million | -- |